• Next-generation intravascular lithotripsy (IVL) catheter resets physicians' expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioning
  • Shockwave C2 Aero enables clinicians to extend Shockwave IVL's clinically-validated mechanism of action to a broader spectrum of calcified coronary lesions

Johnson & Johnson (NYSE:JNJ) announced today the global launch of its Shockwave C2 Aero Coronary IVL Catheter designed for improved deliverability, enhanced lesion crossing and new repositioning capabilities for the treatment of calcified coronary artery disease (CAD).1,2,3 The next-generation coronary IVL catheter leverages Shockwave IVL's unique mechanism of action and the safety and effectiveness profile of its legacy catheters, expanding the company's market-leading IVL portfolio.